Summary
Plexxikon's early stage experimental melanoma drug PLX4032 looks like a "major breakthrough," says one leading researcher after reviewing new data from a small trial.
Analysis
This seems like great news in the fight against melanoma. We already know that melanoma is highly deadly once it metastasizes, and fortunately we often catch it in the early stages because of its ugly appearance superficially.
We do not have great chemotherapeutic options at this time for melanoma, however INF shows some benefit.
As this article says >70% had a >30% tumor reduction.
Unfortunately this is only the early stage trials, and will be a while before we might get to see it on the market and used in practice. Hopefully they push this one.
Promising!
This author consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
